
|Videos|January 17, 2023
Common Molecular Alterations in Advanced RAI-R-DTC
Author(s)Lori J. Wirth, MD
Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Selecting Between IO/TKI and IO/IO Combination Therapy
2
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
3
Unique Benefits Seen With CAR T in AL Amyloidosis
4
CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma
5


































